Skip to main content
Erschienen in: Die Gastroenterologie 4/2021

11.06.2021 | Chronisch-entzündliche Darmerkrankungen | CME

Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen

verfasst von: PD Dr. med. Elisabeth Schnoy, Helmut Messmann, Ralf Kiesslich

Erschienen in: Die Gastroenterologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit chronisch-entzündlichen Darmerkrankungen (CED) haben ein erhöhtes Risiko für die Entwicklung von Kolonkarzinomen. Risikofaktoren sind unter anderem die chronisch-persistierende Entzündungsaktivität und bei der Colitis ulcerosa die Krankheitsausdehnung. Die frühzeitige Detektion von Dysplasien und Frühmalignomen ist durch die Etablierung von entsprechenden hochqualitativen Vorsorgeendoskopien, z. B. mit Chromendoskopie, möglich geworden. Durch eine rechtzeitige risikoadaptierte endoskopische Überwachung kann die Prognose der Patienten deutlich verbessert werden.
Literatur
1.
Zurück zum Zitat Petritsch W, Fuchs S, Berghold A, Bachmaier G, Hogenauer C, Hauer AC, Weiglhofer U, Wenzl HH (2013) Incidence of inflammatory bowel disease in the province of Styria, Austria, from 1997 to 2007: a population-based study. J Crohns Colitis 7:58–69PubMed Petritsch W, Fuchs S, Berghold A, Bachmaier G, Hogenauer C, Hauer AC, Weiglhofer U, Wenzl HH (2013) Incidence of inflammatory bowel disease in the province of Styria, Austria, from 1997 to 2007: a population-based study. J Crohns Colitis 7:58–69PubMed
2.
Zurück zum Zitat Lucendo AJ, Hervias D, Roncero O, Lorente R, Bouhmidi A, Angueira T, Verdejo C, Saluena I, Gonzalez-Castillo S, Arias A (2014) Epidemiology and temporal trends (2000-2012) of inflammatory bowel disease in adult patients in a central region of Spain. Eur J Gastroenterol Hepatol 26:1399–1407PubMed Lucendo AJ, Hervias D, Roncero O, Lorente R, Bouhmidi A, Angueira T, Verdejo C, Saluena I, Gonzalez-Castillo S, Arias A (2014) Epidemiology and temporal trends (2000-2012) of inflammatory bowel disease in adult patients in a central region of Spain. Eur J Gastroenterol Hepatol 26:1399–1407PubMed
3.
Zurück zum Zitat Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Scholmerich J, Rogler G, Timmer A (2008) The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol 20:917–923PubMed Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Scholmerich J, Rogler G, Timmer A (2008) The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Eur J Gastroenterol Hepatol 20:917–923PubMed
4.
Zurück zum Zitat Lophaven SN, Lynge E, Burisch J (2017) The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther 45:961–972PubMed Lophaven SN, Lynge E, Burisch J (2017) The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther 45:961–972PubMed
5.
Zurück zum Zitat Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67:263–268PubMed Crohn BB, Ginzburg L, Oppenheimer GD (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67:263–268PubMed
6.
Zurück zum Zitat Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035PubMed Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035PubMed
7.
Zurück zum Zitat Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMed Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65PubMed
8.
Zurück zum Zitat Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K (2018) Efficacy of vedolizumab in Fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 12:621–626PubMedPubMedCentral Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K (2018) Efficacy of vedolizumab in Fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis 12:621–626PubMedPubMedCentral
9.
Zurück zum Zitat Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van AG, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710PubMed Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van AG, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699–710PubMed
10.
Zurück zum Zitat Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr., Dieleman LA, Katz S, Rutgeerts P (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960PubMed Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr., Dieleman LA, Katz S, Rutgeerts P (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960PubMed
11.
Zurück zum Zitat Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736PubMed Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736PubMed
12.
Zurück zum Zitat Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van AG, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMed Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van AG, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMed
13.
Zurück zum Zitat Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr., Marteau P, Munkholm P, Murdoch TB, Ordas I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van AG, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338PubMed Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr., Marteau P, Munkholm P, Murdoch TB, Ordas I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van AG, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324–1338PubMed
14.
Zurück zum Zitat Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Scholmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031CrossRefPubMed Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Scholmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570–1583. https://​doi.​org/​10.​1053/​j.​gastro.​2020.​12.​031CrossRefPubMed
15.
Zurück zum Zitat Dal BA, Roda G, Argollo M, Peyrin-Biroulet L, Danese S (2020) Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 20:407–412 Dal BA, Roda G, Argollo M, Peyrin-Biroulet L, Danese S (2020) Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 20:407–412
16.
Zurück zum Zitat Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Flejou JF, Carrat F (2013) Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145:166–175PubMed Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Flejou JF, Carrat F (2013) Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145:166–175PubMed
17.
Zurück zum Zitat Jess T, Winther KV, Munkholm P, Langholz E, Binder V (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19:287–293PubMed Jess T, Winther KV, Munkholm P, Langholz E, Binder V (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19:287–293PubMed
18.
Zurück zum Zitat Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2:1088–1095PubMed Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2:1088–1095PubMed
19.
Zurück zum Zitat Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487PubMed Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487PubMed
20.
Zurück zum Zitat Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9:945–965PubMed Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R (2015) European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 9:945–965PubMed
21.
Zurück zum Zitat Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A (2001) Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357:262–266PubMed Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A (2001) Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357:262–266PubMed
22.
Zurück zum Zitat Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, Kuipers EJ, van der Woude CJ (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 106:319–328PubMed Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, Kuipers EJ, van der Woude CJ (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 106:319–328PubMed
23.
Zurück zum Zitat Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMed Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMed
24.
Zurück zum Zitat Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558PubMedPubMedCentral Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558PubMedPubMedCentral
25.
Zurück zum Zitat Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17PubMed Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17PubMed
26.
Zurück zum Zitat Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103:1611–1620PubMed Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103:1611–1620PubMed
27.
Zurück zum Zitat Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ (1993) p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104:1633–1639PubMed Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ (1993) p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104:1633–1639PubMed
28.
Zurück zum Zitat Pereira C, Coelho R, Gracio D, Dias C, Silva M, Peixoto A, Lopes P, Costa C, Teixeira JP, Macedo G, Magro F (2016) DNA damage and oxidative DNA damage in inflammatory bowel disease. J Crohns Colitis 10:1316–1323PubMed Pereira C, Coelho R, Gracio D, Dias C, Silva M, Peixoto A, Lopes P, Costa C, Teixeira JP, Macedo G, Magro F (2016) DNA damage and oxidative DNA damage in inflammatory bowel disease. J Crohns Colitis 10:1316–1323PubMed
29.
Zurück zum Zitat Kewenter J, Ahlman H, Hulten L (1978) Cancer risk in extensive ulcerative colitis. Ann Surg 188:824–828PubMedPubMedCentral Kewenter J, Ahlman H, Hulten L (1978) Cancer risk in extensive ulcerative colitis. Ann Surg 188:824–828PubMedPubMedCentral
30.
Zurück zum Zitat Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN (1980) Malignancy in Crohn’s disease. Gut 21:1024–1029PubMedPubMedCentral Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN (1980) Malignancy in Crohn’s disease. Gut 21:1024–1029PubMedPubMedCentral
31.
Zurück zum Zitat Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19:789–799PubMed Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19:789–799PubMed
32.
Zurück zum Zitat Jess T, Loftus EV Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ III, Munkholm P, Sandborn WJ (2006) Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 12:669–676PubMed Jess T, Loftus EV Jr., Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ III, Munkholm P, Sandborn WJ (2006) Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis 12:669–676PubMed
33.
Zurück zum Zitat Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143:375–381PubMed Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143:375–381PubMed
34.
Zurück zum Zitat Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645PubMed Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645PubMed
35.
Zurück zum Zitat Castano-Milla C, Chaparro M, Gisbert JP (2014) Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 39:645–659PubMed Castano-Milla C, Chaparro M, Gisbert JP (2014) Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 39:645–659PubMed
36.
Zurück zum Zitat Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de AM, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagorowicz E, Raine T, Harbord M, Rieder F (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670PubMed Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de AM, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagorowicz E, Raine T, Harbord M, Rieder F (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis 11:649–670PubMed
38.
Zurück zum Zitat Manninen P, Karvonen AL, Huhtala H, Aitola P, Hyoty M, Nieminen I, Hemminki H, Collin P (2013) The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohns Colitis 7:e551–e557PubMed Manninen P, Karvonen AL, Huhtala H, Aitola P, Hyoty M, Nieminen I, Hemminki H, Collin P (2013) The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohns Colitis 7:e551–e557PubMed
39.
Zurück zum Zitat Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813–1816PubMedPubMedCentral Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813–1816PubMedPubMedCentral
40.
Zurück zum Zitat Velayos FS, Loftus EV Jr., Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130:1941–1949PubMed Velayos FS, Loftus EV Jr., Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130:1941–1949PubMed
41.
Zurück zum Zitat Mahmoud R, Shah SC, Ten Hove JR, Torres J, Mooiweer E, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2019) No association between pseudopolyps and colorectal neoplasia in patients with inflammatory bowel diseases. Gastroenterology 156:1333–1344PubMed Mahmoud R, Shah SC, Ten Hove JR, Torres J, Mooiweer E, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2019) No association between pseudopolyps and colorectal neoplasia in patients with inflammatory bowel diseases. Gastroenterology 156:1333–1344PubMed
42.
Zurück zum Zitat Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR (2013) Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 11:1601–1608PubMed Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR (2013) Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 11:1601–1608PubMed
43.
Zurück zum Zitat Mahmoud R, Shah SC, Torres J, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Harpaz N, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2020) Association between indefinite dysplasia and advanced neoplasia in patients with inflammatory bowel diseases undergoing surveillance. Clin Gastroenterol Hepatol 18:1518–1527PubMed Mahmoud R, Shah SC, Torres J, Castaneda D, Glass J, Elman J, Kumar A, Axelrad J, Harpaz N, Ullman T, Colombel JF, Oldenburg B, Itzkowitz SH (2020) Association between indefinite dysplasia and advanced neoplasia in patients with inflammatory bowel diseases undergoing surveillance. Clin Gastroenterol Hepatol 18:1518–1527PubMed
44.
Zurück zum Zitat Sonnenberg A, Genta RM (2015) Epithelial dysplasia and cancer in IBD strictures. J Crohns Colitis 9:769–775PubMed Sonnenberg A, Genta RM (2015) Epithelial dysplasia and cancer in IBD strictures. J Crohns Colitis 9:769–775PubMed
45.
Zurück zum Zitat Lee HS, Park SH, Yang SK, Ye BD, Kim JH, Kim SO, Soh JS, Lee S, Bae JH, Lee HJ, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH (2015) The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol 50:188–196PubMed Lee HS, Park SH, Yang SK, Ye BD, Kim JH, Kim SO, Soh JS, Lee S, Bae JH, Lee HJ, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH (2015) The risk of colorectal cancer in inflammatory bowel disease: a hospital-based cohort study from Korea. Scand J Gastroenterol 50:188–196PubMed
46.
Zurück zum Zitat Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabate JM, Peyrin-Biroulet L, Colombel JF, Allez M, Flejou JF, Kirchgesner J, Svrcek M (2018) High risk of anal and rectal cancer in patients with anal and/or Perianal Crohn’s disease. Clin Gastroenterol Hepatol 16:892–899PubMed Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabate JM, Peyrin-Biroulet L, Colombel JF, Allez M, Flejou JF, Kirchgesner J, Svrcek M (2018) High risk of anal and rectal cancer in patients with anal and/or Perianal Crohn’s disease. Clin Gastroenterol Hepatol 16:892–899PubMed
47.
Zurück zum Zitat Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338PubMed Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE (1996) Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 110:331–338PubMed
48.
Zurück zum Zitat D’Haens GR, Lashner BA, Hanauer SB (1993) Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 88:1174–1178PubMed D’Haens GR, Lashner BA, Hanauer SB (1993) Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 88:1174–1178PubMed
49.
Zurück zum Zitat Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Siersema PD, Vleggaar FP (2009) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15:1331–1336PubMed Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Siersema PD, Vleggaar FP (2009) More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 15:1331–1336PubMed
50.
Zurück zum Zitat Unal NG, Ozutemiz O, Tekin F, Turan I, Osmanoglu N (2019) Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turk J Gastroenterol 30:139–147PubMed Unal NG, Ozutemiz O, Tekin F, Turan I, Osmanoglu N (2019) Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turk J Gastroenterol 30:139–147PubMed
51.
Zurück zum Zitat Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM (1998) Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115:1079–1083PubMed Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM (1998) Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 115:1079–1083PubMed
52.
Zurück zum Zitat Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R (2015) SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 81:489–501PubMed Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R (2015) SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 81:489–501PubMed
53.
Zurück zum Zitat German Society for Digestive and Metabolic Diseases (DGVS) (2019) Updated S3-guideline ulcerative colitis. Z Gastroenterol 57:162–241 German Society for Digestive and Metabolic Diseases (DGVS) (2019) Updated S3-guideline ulcerative colitis. Z Gastroenterol 57:162–241
54.
Zurück zum Zitat Hlavaty T, Huorka M, Koller T, Zita P, Kresanova E, Rychly B, Toth J (2011) Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 23:680–689PubMed Hlavaty T, Huorka M, Koller T, Zita P, Kresanova E, Rychly B, Toth J (2011) Colorectal cancer screening in patients with ulcerative and Crohn’s colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol 23:680–689PubMed
55.
Zurück zum Zitat Murthy S, Goetz M, Hoffman A, Kiesslich R (2012) Novel colonoscopic imaging. Clin Gastroenterol Hepatol 10:984–987PubMed Murthy S, Goetz M, Hoffman A, Kiesslich R (2012) Novel colonoscopic imaging. Clin Gastroenterol Hepatol 10:984–987PubMed
56.
Zurück zum Zitat Buchner AM, Shahid MW, Heckman MG, McNeil RB, Cleveland P, Gill KR, Schore A, Ghabril M, Raimondo M, Gross SA, Wallace MB (2010) High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol 8:364–370PubMed Buchner AM, Shahid MW, Heckman MG, McNeil RB, Cleveland P, Gill KR, Schore A, Ghabril M, Raimondo M, Gross SA, Wallace MB (2010) High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. Clin Gastroenterol Hepatol 8:364–370PubMed
57.
Zurück zum Zitat Brooker JC, Saunders BP, Shah SG, Thapar CJ, Thomas HJ, Atkin WS, Cardwell CR, Williams CB (2002) Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 56:333–338PubMed Brooker JC, Saunders BP, Shah SG, Thapar CJ, Thomas HJ, Atkin WS, Cardwell CR, Williams CB (2002) Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 56:333–338PubMed
58.
Zurück zum Zitat Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880–888PubMed Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124:880–888PubMed
59.
Zurück zum Zitat Kiesslich R, Neurath MF (2004) Chromoendoscopy: an evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis 10:695–696PubMed Kiesslich R, Neurath MF (2004) Chromoendoscopy: an evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis 10:695–696PubMed
60.
Zurück zum Zitat Kiesslich R, Neurath MF (2004) Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 53:165–167PubMedPubMedCentral Kiesslich R, Neurath MF (2004) Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 53:165–167PubMedPubMedCentral
61.
Zurück zum Zitat Kiesslich R, Neurath MF (2015) Advances in detection and management of dysplasia in inflammatory bowel disease: Is endoscopic submucosal dissection ready for prime time in inflammatory bowel disease? Gastrointest Endosc 82:739–741PubMed Kiesslich R, Neurath MF (2015) Advances in detection and management of dysplasia in inflammatory bowel disease: Is endoscopic submucosal dissection ready for prime time in inflammatory bowel disease? Gastrointest Endosc 82:739–741PubMed
62.
Zurück zum Zitat Carballal S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, Vera MI, Marin-Garbriel JC, Diaz-Tasende J, Marquez L, Alvarez MA, Hernandez L, De CL, Gordillo J, Puig I, Vega P, Bustamante-Balen M, Acevedo J, Penas B, Lopez-Ceron M, Ricart E, Cuatrecasas M, Jimeno M, Pellise M (2018) Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 67:70–78PubMed Carballal S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, Vera MI, Marin-Garbriel JC, Diaz-Tasende J, Marquez L, Alvarez MA, Hernandez L, De CL, Gordillo J, Puig I, Vega P, Bustamante-Balen M, Acevedo J, Penas B, Lopez-Ceron M, Ricart E, Cuatrecasas M, Jimeno M, Pellise M (2018) Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut 67:70–78PubMed
63.
Zurück zum Zitat Kandiah K, Subramaniam S, Thayalasekaran S, Chedgy FJ, Longcroft-Wheaton G, Fogg C, Brown JF, Smith SC, Iacucci M, Bhandari P (2020) Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). Gut. https://doi.org/10.1136/gutjnl-2020-320980CrossRefPubMed Kandiah K, Subramaniam S, Thayalasekaran S, Chedgy FJ, Longcroft-Wheaton G, Fogg C, Brown JF, Smith SC, Iacucci M, Bhandari P (2020) Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). Gut. https://​doi.​org/​10.​1136/​gutjnl-2020-320980CrossRefPubMed
64.
Zurück zum Zitat Clarke K, Kang M, Gorrepati VS, Stine JG, Tinsley A, Williams E, Moyer M, Coates M (2020) Dysplasia detection is similar between chromoendoscopy and high-definition white-light colonoscopy in inflammatory bowel disease patients: a US-matched case-control study. Int J Colorectal Dis 35:2301–2307PubMed Clarke K, Kang M, Gorrepati VS, Stine JG, Tinsley A, Williams E, Moyer M, Coates M (2020) Dysplasia detection is similar between chromoendoscopy and high-definition white-light colonoscopy in inflammatory bowel disease patients: a US-matched case-control study. Int J Colorectal Dis 35:2301–2307PubMed
65.
Zurück zum Zitat Westwood DA, Alexakis N, Connor SJ (2012) Transparent cap-assisted colonoscopy versus standard adult colonoscopy: a systematic review and meta-analysis. Dis Colon Rectum 55:218–225PubMed Westwood DA, Alexakis N, Connor SJ (2012) Transparent cap-assisted colonoscopy versus standard adult colonoscopy: a systematic review and meta-analysis. Dis Colon Rectum 55:218–225PubMed
66.
Zurück zum Zitat Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M (2016) Targeted biopsies identify larger proportions of patients with colonic neoplasia undergoing high-definition colonoscopy, dye chromoendoscopy, or electronic virtual chromoendoscopy. Clin Gastroenterol Hepatol 14:704–712PubMed Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M (2016) Targeted biopsies identify larger proportions of patients with colonic neoplasia undergoing high-definition colonoscopy, dye chromoendoscopy, or electronic virtual chromoendoscopy. Clin Gastroenterol Hepatol 14:704–712PubMed
67.
Zurück zum Zitat Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T (2016) Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 151:1122–1130PubMed Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T (2016) Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology 151:1122–1130PubMed
68.
Zurück zum Zitat Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L (2008) Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 103:2342–2349PubMed Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L (2008) Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 103:2342–2349PubMed
69.
Zurück zum Zitat Kiesslich R, Neurath MF (2017) Advanced endoscopy imaging in inflammatory bowel diseases. Gastrointest Endosc 85:496–508PubMed Kiesslich R, Neurath MF (2017) Advanced endoscopy imaging in inflammatory bowel diseases. Gastrointest Endosc 85:496–508PubMed
70.
Zurück zum Zitat Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Gotz M, Katsanos KH, Kiesslich R, Ordas I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7:982–1018PubMed Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Gotz M, Katsanos KH, Kiesslich R, Ordas I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7:982–1018PubMed
71.
Zurück zum Zitat Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107:117–120PubMed Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107:117–120PubMed
72.
Zurück zum Zitat Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT (2007) 5‑Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13:367–371PubMed Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT (2007) 5‑Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13:367–371PubMed
73.
Zurück zum Zitat Lyakhovich A, Gasche C (2010) Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 31:202–209PubMed Lyakhovich A, Gasche C (2010) Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 31:202–209PubMed
74.
Zurück zum Zitat Stolfi C, Pallone F, Monteleone G (2012) Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol 2012:980458PubMedPubMedCentral Stolfi C, Pallone F, Monteleone G (2012) Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol 2012:980458PubMedPubMedCentral
Metadaten
Titel
Überwachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen
verfasst von
PD Dr. med. Elisabeth Schnoy
Helmut Messmann
Ralf Kiesslich
Publikationsdatum
11.06.2021
Verlag
Springer Medizin
Erschienen in
Die Gastroenterologie / Ausgabe 4/2021
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-021-00536-0

Weitere Artikel der Ausgabe 4/2021

Die Gastroenterologie 4/2021 Zur Ausgabe

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Abstracts

Mitteilungen der NDGG

Mitteilungen der NDGG

Mitteilungen der Mitteldeutschen Gesellschaft für Gastroenterologie

Mitteilungen der Mitteldeutschen Gesellschaft für Gastroenterologie

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?